medigraphic.com

2025, Number 2

<< Back Next >>

Enf Infec Microbiol 2025; 45 (2)

Latent tuberculosis in patients living with HIV on the southern border of Chiapas

Jiménez-Villanueva EG, Contreras-López S, Fuentes-Monterrosa T, Martínez-Rodríguez JC, Betanzos-López A

Language: Spanish
References: 45
Page: 86-91
PDF size: 156.95 Kb.


ABSTRACT

Background: approximately one quarter of the world’s population has latent tuberculosis infection (LTBI). The risk of LTBI progression to active infection is significant and in people with HIV infection the risk increases up to 80%.
Methodology: retrospective, descriptive and cross-sectional study, in a cohort of patients with HIV infection attended by the infectious disease service of the HRAE Ciudad Salud from 2016-2019. The prevalence of LTBI was determined by interferon gamma release assay (IGRA), a descriptive analysis of sociodemographic and biochemical variables was developed, and a multivariate logistic regression was performed to correlate the results of the IGRA test and CD4 T lymphocyte count.
Results: 63 people were studied, 81% men, mean age 34.6 years. 74% with severe immunosuppression (LT CD4 CD4 count ‹200 cells/mm3). 84% of tests performed were QuantiFERON ®-TB Gold In-Tube; 13% of tests were positive. A prevalence of LTBI was determined to be 8%. No correlation was found between IGRA result and LT CD4 count.
Conclusion: the prevalence of LTBI in patients living with HIV is lower than estimated in the general population worldwide and nationally. No statistically significant relationship was identified between immune status (LT CD4) and IGRA’S test results. Host variables and clinical presentation of TB should be comprehensively evaluated when obtaining a negative IGRA result.


REFERENCES

  1. “Global tuberculosis report 2018”, Ginebra, World HealthOrganization, 2018.

  2. Centro Nacional de Programas Preventivos y Controlde Enfermedades, “Situación epidemiológica México2021”, Secretaría de Salud. Disponible en: https://www.gob.mx/cms/uploads/attachment/file/722796/1. SITUACI_N_EPIDEMIOL_GICA_2021_preliminar.pdf.

  3. Houben, R.M. y Dodd, P.J., “The global burden of latenttuberculosis infection: a re-estimation using mathematicalmodelling”, plos Med, 2016, 13 (10): e1002152.

  4. Blumberg, H.M., Leonard, M.K. Jr y Jasmer, R.M., “Updateon the treatment of tuberculosis and latent tuberculosisinfection”, jama, 2005, 293: 2776-2784.

  5. Small, P. y Fujiwara, P., “Management of tuberculosis inthe United States”, N Engl J Med, 2001, 345 (3): 189-200.

  6. World Health Organization, “Global tuberculosis control:surveillance, planning, financing”, Ginebra, who, 2004.

  7. Opie, E. y Aronson, J., “Tubercle bacilli in latent tuberculouslesions and in lung tissue without tuberculouslesions”, Arch Pathol Lab Med, 1927, 4: 21.

  8. World Health Organization, “Guidelines on the managementof latent tuberculosis infection (who/htm/tb/2015.01)”, Ginebra, who, 2015, 38 pp.

  9. Conde, M.B., Melo, F.A., Marques, A.M., Cardoso, N.C.,Pinheiro, V.G., Dalcin, P.T. et al., “III Brazilian thoracic associationguidelines on tuberculosis”, J Bras Pneumol,2009, 35: 1018-1048.

  10. Rose Jr, C.E., Zerbe, G.O., Lantz, S.O. y Bailey, W.C.,“Establishing priority during investigation of tuberculosiscontacts”, Am Rev Respir Dis, 1979, 119: 603-609.

  11. World Health Organization, “who policy on collaborativetb/hiv activities. Guidelines for national programmes andother stakeholders”, Ginebra, who, 2012. Disponible en:https://reliefweb.int/sites/reliefweb.int/files/resources/Full_Report_3595.pdf.

  12. Field, S.K., Escalante, P., Fisher, D.A., Ireland, B. e Irwin,R.S., “Cough due to tb and other chronic infections:Chest guideline and expert panel report”, Chest, 2018,153 (2): 467-497.

  13. Wang, X.Y., Su, B.Y., Chen, Z.Y., Kuang, H.B., Guan, P.,Cao, Z.Z. y Tan, Y.J., “Comparison of Quantiferon-tb GoldPlus and Quantiferon-tb Gold In Tube in the diagnosis ofpulmonary tuberculosis”, Zhonghua Jie He He Hu Xi ZaZhi, 2022, 45 (5): 445-452.

  14. Qiagen, “Instrucciones de uso del Quantiferon®-tb GoldPlus elisa Kit”, 2023.

  15. Rangaka, M.X., Cavalcante, S.C., Martinson, N., Marais,B.J., Thim, S., Swaminathan, S. y Chaisson, R.E., “Controllingthe seedbeds of tuberculosis: diagnosis andtreatment of tuberculosis infection”, Lancet, 2015, 386:2244-2253.

  16. Centro Nacional para la Prevención y Control del vih/sida(Censida), Primer trimestre 2019, consultado en la páginade Censida.

  17. Centro Nacional de Programas Preventivos y Controlde Enfermedades (Censida), Situación epidemiológicaMéxico 2015-2016, Secretaría de Salud, consultado enla página de Censida.

  18. Garfein, R.S., Lozada, R., Liu, L., Laniado-Laborin, R.,Rodwell, T.C., Deiss, R. et al., “High prevalence of latenttuberculosis infection among injection drug users in Tijuana,Mexico”, ijtld, 2009, 13 (5): 626-632.

  19. Garfein, R.S., Laniado-Laborin, R., Rodwell, T.C., Lozada,R., Deiss, R., Burgos, J.L., et al., “Latent tuberculosisamong persons at risk for infection with hiv, Tijuana,Mexico”, Emerging Infectious Diseases, 2010, 16 (5),757-763.

  20. Lin, W.C., Lin, H.H., Lee, S.S., Sy, C.L., Wu, K.S., Chen,J.K., Tsai, H.C. y Chen, Y.S., “Prevalence of latent tuberculosisinfection in persons with and without humanimmunodeficiency virus infection using two interferon-gamma release assays and tuberculin skin test ina low human immunodeficiency virus prevalence, intermediatetuberculosis-burden country”, J MicrobiolImmunol Infect, 2016, 49 (5): 729-736.

  21. Goletti, D., Navarra, A., Petruccioli, E., Cimaglia, C.,Compagno, M., Cuzzi, G. et al., “Latent tuberculosis infectionscreening in persons newly-diagnosed with hivinfection in Italy: a multicentre study promoted by theItalian Society of Infectious and Tropical Diseases”, Int JInfect Dis, 2020, 92: 62-68.

  22. Nguyen, D.T., Teeter, L.D., Graves, J. y Graviss, E.A.,“Characteristics associated with negative interferon-γrelease assay results in culture-confirmed tuberculosispatients, Texas, USA, 2013-2015”, eid, 2018, 24 (3), 534-540.

  23. Niguse, S., Desta, K., Gebremichael, G., Gebrezgeaxier,A., Getahun, M. y Kassa, D., “Quantiferon-tb Gold In-tubetest for the diagnosis of active and latent tuberculosis inselected health facilities of Addis Abeba, Ethiopia”, bmcResearch Notes, 2018, 11 (1): 293.

  24. Akolo, C., Adetifa, I., Shepperd, S. y Volmink, J., “Treatmentof latent tuberculosis infection in hiv infected persons”,Cochrane Database Syst Rev, 2010, 1: cd000171.

  25. Burlamaqui Klautau, G., Ferreira da Mota, N.V., CostaSalles, M.J., Nascimento Burattini, M., Silva Rodrigues,D., “Interferon-γ release assay as a sensitive diagnostictool of latent tuberculosis infection in patients with hiv:a cross-sectional study”, bmc Infectious Diseases, 2018,18 (1): 585.

  26. Sauzullo, I., Mengoni, F., Ermocida, A., Massetti, A.P.,D’Agostino, C., Russo, G. et al., “Interferon-γ releaseassay in hiv-infected patients with active tuberculosis:impact of antituberculous drugs on host immune response”,New Microbiologica, 2014; 37 (2): 153-161.

  27. Metcalfe, J.Z., Everett, C.K., Steingart, K.R., Cattamanchi,A., Huang, L., Hopewell, P.C. y Pai, M. “Interferon-γrelease assays for active pulmonary tuberculosis diagnosisin adults in low- and middle-income countries:systematic review and meta-analysis”, J Infect Dis,2011, 15: S1120-S1129.

  28. Brock, I., Ruhwald, M., Lundgren, B., Westh, H., Mathiesen,L.R. y Ravn, P., “Latent tuberculosis in hivpositive, diagnosed by the M. tuberculosis specific interferon-gamma test”, Respir Res, 2006, 7: 56.

  29. Sauzullo, I., Mengoni, F., Scrivo, R., Valesini, G., Potenza,C., Skroza, N. et al., “Evaluation of Quantiferon-tb GoldIn-Tube in human immunodeficiency virus infection andin patient candidates for anti-tumor necrosis factor-alphatreatment”, Int J Tuberc Lung Dis, 2010, 14: 834-840.

  30. Hang, N.T., Lien, L.T., Kobayashi, N., Shimbo, T., Sakurada,S., Thuong, P.H. et al., “Analysis of factors loweringsensitivity of interferon-g release assay for tuberculosis”,plos One, 2011, 6: e23806.

  31. Kim, E.Y., Park, M.S., Kim, Y.S., Kim, S.K., Chang, J. yKang, Y.A., “Risk factors for false-negative results ofQuantiferon-tb Gold In-tube assay in non-hiv-infectedpatients with culture-confirmed tuberculosis”, DiagnMicrobiol Infect Dis, 2011, 70: 324e9.

  32. Diel, R., Loddenkemper, R. y Nienhaus, A., “Evidence-based comparison of commercial interferon-gammarelease assays for detecting active tb: a meta-analysis”,Chest, 2010, 137: 952e68.

  33. Banfield, S., Pascoe, E., Thambiran, A., Siafarikas, A. yBurgner, D., “Factors associated with the performanceof a blood-based interferon-g release assay in diagnosingtuberculosis”, plos One, 2012, 7: e38556.

  34. Jeong, S.J., Han, S.H., Kim, C.O., Baek, J.H., Jin, S.J., Ku,N.S. et al., “Predictive factors for indeterminate resulton the Quantiferon test in an intermediate tuberculosis-burden country”, J Infect, 2011, 62: 347e54.

  35. Jeon, Y.L., Nam, Y., You, E., Yang, J.J., Kim, M.J., Cho,S. et al., “Factors influencing discordant results of theQuantiferon-tb Gold In-tube test in patients with activetb”, J Infect, 2013, 67 (4): 288-293.

  36. Herrera, V., Yeh, E., Murphy, K., Parsonnet, J. y Banaei,N., “Immediate incubation reduces indeterminate resultsfor Quantiferon-tb Gold In-Tube Assay”, J Clin Microbiol,2010, 48 (8): 2672-2676.

  37. Min, J.-W., Lee, H.-Y., Lee, J.S., Lee, J., Chung, J.H., Han,S.K. y Yim, J.-J., “Effect of prolonged incubation timeon results of the Quantiferon-tb Gold In-Tube Assay fordiagnosis of latent tuberculosis infection”, Clinical andVaccine Immunology, 2013, 20 (9): 1377-1380.

  38. Doberne, D., Gaur, R.L. y Banaei, N., “Preanalytical delayreduces sensitivity of Quantiferon-tb Gold In-Tube Assayfor detection of latent tuberculosis infection”, J Clin Microbiol,2011, 49 (8): 3061-3064.

  39. Gaur, R.L., Pai, M. y Banaei, N., “Impact of blood volume,tube shaking, and incubation time on reproducibilityof Quantiferon-tb Gold In-Tube Assay”, J Clin Microbiol,2013, 51 (11): 3521-3526.

  40. Tebruegge, M., Curtis, N., Clifford, V., Fernández-Turienzo,C., Klein, N., Fidler, K. et al., “Seasonal variation inthe performance of Quantiferon-tb Gold In-Tube assaysused for the diagnosis of tuberculosis infection”, Tuberculosis,2018, 110: 26-29.

  41. Kwon, Y.S., Kim, Y.H., Jeon, K., Jeong, B.H., Ryu, Y.J.,Choi, J.C. et al., “Factors that Predict Negative Resultsof Quantiferon-tb Gold In-Tube Test in patients with culture-confirmed tuberculosis: a multicenter retrospectivecohort study”, plos One, 2015, 10 (6): e0129792.

  42. Cho, K., Cho, E., Kwon, S., Im, S., Sohn, I., Song, S.,Kim, H. y Kim, S., “Factors associated with indeterminateand false negative results of Quantiferon-tb GoldIn-Tube Test in active tuberculosis”, Tuberc Respir Dis(Seúl), 2012, 72 (5): 416-425.

  43. Song, K.H., Jeon, J.H., Park, W.B., Kim, S.H., Park, K.U.,Kim, N.J. et al., “Usefulness of the whole-blood interferon-gamma release assay for diagnosis of extrapulmonarytuberculosis”, Diagn Microbiol Infect Dis, 2009, 63(2):182-187.

  44. Yamasue, M., Komiya, K., Usagawa, Y., Umeki, K., Nureki,S.I., Ando, M. et al., “Factors associated with falsenegative interferon-γ release assay results in patientswith tuberculosis: a systematic review with meta-analysis”,Sci Rep, 2020, 10 (1): 1607.

  45. Kim, Y.J., Kang, J.Y., Kim, S.I., Chang, M.S., Kim, Y.R. yPark ,Y.J., “Predictors for false-negative Quantiferon-tbGold assay results in patients with extrapulmonary tuberculosis”,bmc Infect Dis, 2018, 10, 18(1): 457.




2020     |     www.medigraphic.com